Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
The Multiple Dose of PK/PD Study of SHR2285 Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Thrombus
- Interventions
- Drug: SHR2285 tabletDrug: Placebo
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT04229433
- Locations
- 🇨🇳
Zhejing Provincial People's Hospital, Hangzhou, Zhejiang, China
A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy
Phase 3
- Conditions
- Fallopian Tube CancerOvarian CancerPrimary Peritoneal Carcinoma
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 690
- Registration Number
- NCT04229615
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer
Phase 1
Completed
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2020-01-14
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT04228601
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
🇨🇳Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China
Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)
Phase 3
- Conditions
- PD-L1 Positive Non-small Cell Lung Cancer
- Interventions
- Biological: Camrelizumab 200mg
- First Posted Date
- 2019-12-18
- Last Posted Date
- 2020-05-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 762
- Registration Number
- NCT04203485
A Trial of Dexmedetomidine Hydrochloride Nasal Spray in Preoperative Sedation of Children
Phase 1
Completed
- Conditions
- Preoperative Sedation
- Interventions
- First Posted Date
- 2019-12-16
- Last Posted Date
- 2020-09-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT04200235
- Locations
- 🇨🇳
Beijing children's hospital, capital medical university, Beijing, Beijing, China
Food Effect Study of DDO-3055 Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Anemia in Chronic Kidney Disease
- Interventions
- Drug: DDO-3055 tablet
- First Posted Date
- 2019-12-13
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT04197778
- Locations
- 🇨🇳
Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Effect of Fluconazole on PK of Fluzoparib in Healthy Male Subjects
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2019-12-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT04193319
- Locations
- 🇨🇳
Early Cancer Research Center of Hunan Cancer Hospital, Hunan, Hunan, China
A Safety and Efficacy Study of SHR4640 and Febuxostat in Subjects With Hyperuricemia
Phase 2
- Conditions
- Hyperuricemia
- Interventions
- Drug: SHR4640 dose1 plus Febuxostat dose1Drug: SHR4640 dose1 plus Febuxostat dose2Drug: SHR4640 dose2 plus Febuxostat dose3
- First Posted Date
- 2019-11-29
- Last Posted Date
- 2019-12-02
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT04180982
The Drug-Drug Interaction of SHR4640 and Febuxostat in Patients With Hyperuricemia
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT04157959
- Locations
- 🇨🇳
The Affiliated Hospital of QingDao University, Qingdao, Shan Dong, China
A Clinical Study of SHR-1314 Injection in the Treatment of Moderate to Severe Plaque Psoriasis in Adults
Phase 2
Suspended
- Conditions
- Plaque Psoriasis
- Interventions
- Biological: IL-17A AntagonistBiological: Placebos
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2020-03-23
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT04121143
- Locations
- 🇨🇳
Shanghai Hengrui Pharmaceutical Co., Ltd., Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath